Toronto, Ontario–(Newsfile Corp. – April 13, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that an initial phase of the Brazilian study of the AcuVid™ saliva-based rapid antigen test has been completed. Dr. Ricardo Fujiwara, from the Federal University of Minas Gerais, stated that, “The AcuVid™ initial results confirm the sensitivity and specificity results achieved in Therma’s development studies of the AcuVid™ test against the SARS-CoV-2 first identified strain which originated from Wuhan, China.”
Therma Bright and its R&D team are now initiating an additional second phase study to optimize AcuVid™, in collaboration with Safetest Diagnósticos and University of Minas Gerais, to substantiate AcuVid™ test’s ability to detect known variants that are currently circulating worldwide.
All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. When a virus replicates or makes copies of itself, it sometimes changes, which is normal for a virus. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus.
Rob Fia, CEO, commented, “We are pleased that our Brazil study for our AcuVid™ test confirms the results from our development studies. We will now test AcuVid™ with the known variants to validate its effectiveness and, if necessary, optimize the test to detect these variants.”
Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
